Navigation Links
Molecular aberration signals cancer
Date:2/19/2014

Several scientists, including one at Simon Fraser University, have made a discovery that strongly links a little understood molecule, which is similar to DNA, to cancer and cancer survival.

EMBO Reports, a life sciences journal published by the European Molecular Biology Organization, has just published online the scientists' findings about small non-coding RNAs.

While RNA is known to be key to our cells' successful creation of proteins, the role of small non-coding RNAs, a newly discovered cousin of the former, has eluded scientific understanding for the most part. Until now, it was only surmised that most of these molecules had nothing to do with protein production.

However, scientists at SFU, the University of British Columbia and the B.C. Cancer Agency have discovered that many non-coding RNAs are perturbed in cancerous human cells, including breast and lung, in a specific way. The disturbance, which manifests itself as shorter than normal molecular messaging, also occurs at a specific spot on genes.

"These two identifiable characteristics give cancer-causing non-coding RNAs a chemical signature that makes it easy for scientists to identify them in the early stages of many different types of cancer," says Steven Jones.

The SFU molecular biology and biochemistry professor is this study's senior author, and the associate director and head of bioinformatics at the B.C. Cancer Agency's Genome Sciences Centre.

"These molecules' existence can also be used to classify cancer patients into subgroups of individuals with different survival outcomes," adds Jones. "While the precise reason why a tumour would change the behaviour of genes in this way is not known, it is likely that it represents a mechanism by which the cancer can subvert and takeover the normally well controlled activity of our genes."

This study uncovered non-coding RNAs' cancerous role by using high-throughput sequencing techniques to analyse reams of genetic information on normal and diseased tissue as part of the Cancer Genome Atlas project.

The Cancer Genome Atlas is an ambitious project to characterize the genetic material of more than 500 tumours from more than 20 different cancers. The project provides a goldmine of data for bioinformaticians such as Jones.


'/>"/>

Contact: Carol Thorbes
cthorbes@sfu.ca
778-782-3035
Simon Fraser University
Source:Eurekalert

Related medicine news :

1. Study uncovers molecular keys to invasive bladder cancer
2. Short circuit in molecular switch intensifies pain
3. Molecular nano-spies to make light work of disease detection
4. Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
5. Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
6. New molecular targets identified in some hard-to-treat melanomas provide potential treatment option
7. The Association for Molecular Pathology releases position statement on LDTs
8. Polymer coatings based on molecular structures
9. Supercomputers help ORNL researchers identify key molecular switch that controls cell behavior
10. Mayo Clinic: Drug induces morphologic, molecular and clinical remissions in myelofibrosis
11. Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) Acquires the First FDA Approved High-Throughput DNA Sequencing Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: